3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Sarcoma
1
Lymphoid
1
Gastrointestinal
1
CNS
1
Conditions
Sarcoma
2
Gliosarcoma
2
Glioblastoma
2
Stomach Neoplasms
1
Neuroblastoma
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Neoplasm Metastasis
1
Hematologic Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Brain Neoplasms
1
Interventions
Cyclophosphamide
4
fludarabine phosphate
3
fludarabine
2
Whole-Body Irradiation
2
Tacrolimus
2
Mycophenolic Acid
2
Cytarabine
2
Azacitidine
2
venetoclax
1
thymoglobulin
1
tazemetostat
1
romidepsin
1
quizartinib
1
plerixafor
1
glucarpidase
1
cc-486
1
capmatinib
1
aldesleukin
1
Zoledronic Acid
1
Vincristine
1
Transplantation
1
Thiotepa
1
Spironolactone
1
Rituximab
1
Rifampin
1
Pravastatin
1
Polymerase Chain Reaction
1
Palliative Care
1
Methotrexate
1
Melphalan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
capmatinib
×
Sarcoma
×
Clear all
NCT06988475
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled